Shenzhen Fapon Biotherapy

Fapon Biopharma is a clinical-stage biotechnology company and a subsidiary of Fapon Biotech, a leading global provider of in vitro diagnostic (IVD) solutions. Founded in 2015, the company specializes in the discovery and development of innovative biologics, including therapeutic antibodies and fusion proteins, primarily for oncology and autoimmune diseases. Its lead candidate, FP008, is a first-in-class anti-PD-1 x IL-10M fusion protein currently in Phase 1 clinical trials for the treatment of solid tumors refractory to existing immunotherapies. Fapon Biopharma utilizes several proprietary technology platforms, such as FILTEN™ for immunocytokines and a Bi/Tri-TCE platform for multi-specific T-cell engagers, to address significant unmet medical needs. The company maintains research and development facilities in Dongguan and Shanghai, China, and actively seeks global partnerships for its pipeline assets.